MedTrace Logo

Chinese Herb for the Treatment of Depression and Anxiety Disorders

NCT03323697 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-10-27

No results posted yet for this study

Summary

Anxiety and depression are currently among the ten most important public health concerns, and in recent years, have reached epidemic proportions. Anxiety is recognized as the main risk factor for many diseases including cardiovascular, metabolic and neuropsychiatric disorders. Current anxiolytic medications have a relatively low success rate (\~50%) and are associated with many deleterious side-effects. The investigators aim to investigate the efficacy, safety, and tolerability of a novel herbal treatment on anxiety and depression symptoms in a 6-week double-blind randomized trial.

Conditions

  • Depression, Anxiety

Interventions

OTHER

SZ-05

2.5g a day (3 capsules twice a day)

DRUG

Escitalopram Pill

10 mg capsule plus 5 placebo capsules

Sponsors & Collaborators

  • The Academic College of Tel-Aviv Yaffo

    collaborator OTHER

  • Mazra Mental Health Center

    lead OTHER

Principal Investigators

  • Efrat City, MD · Mazor MHC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-28
Primary Completion
2018-09-01
Completion
2018-12-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03323697 on ClinicalTrials.gov